A trial miss for French metabolic specialist Genfit (Euronext: GNFT) has sent investors running scared in pre-market trading.
Ahead of the opening bell in New York, shares in the company were down over 60%, after the firm revealed the Phase III RESOLVE-IT study of elafibranor missed its primary endpoint.
The response rate was 19.2% for people who received elafibranor, a dual PPARα/δ agonist, compared to 14.7% for people in the placebo arm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze